A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

ClinicalTrials.gov ID: NCT06888921

Public ClinicalTrials.gov record NCT06888921. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jun 25, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Adaptive Clinical Platform Trial to Evaluate the Safety and Efficacy of COM701 as Monotherapy or Combination Therapy as Maintenance Therapy in Participants With Relapsed Platinum Sensitive Ovarian Cancer (PSOC)

Study identification

NCT ID: NCT06888921
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Compugen Ltd; Industry
Enrollment: 60 participants

Conditions and interventions

Conditions

Interventions

COM701 Drug
Normal Saline Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 20, 2025
Primary completion: Feb 28, 2027
Completion: Feb 28, 2027
Last update posted: Mar 31, 2026

2025 – 2027

United States locations

U.S. sites: 14
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Georgia Cancer Center at Augusta University	Augusta	Georgia	30912	Recruiting
The University of Chicago Medical Center	Chicago	Illinois	60637	Recruiting
Northwestern Memorial Hospital	Warrenville	Illinois	60555	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Corewell Health	Grand Rapids	Michigan	49503	Recruiting
Memorial Sloan Kettering Cancer Center- Main Campus	New York	New York	10065	Recruiting
University of Rochester Medical Center	Rochester	New York	14642	Recruiting
Levine Cancer Institute	Charlotte	North Carolina	28204	Recruiting
Ohio State University Wexner Medical Center Gynecologic Oncology at Mill Run	Hilliard	Ohio	43026	Recruiting
OU Health Stephenson Cancer Center	Oklahoma City	Oklahoma	73104	Recruiting
UPMC Magee- Womens Hospital	Pittsburgh	Pennsylvania	15213	Recruiting
Avera Cancer Institute	Sioux Falls	South Dakota	57105	Recruiting
West Cancer Center	Germantown	Tennessee	38138	Withdrawn
UVA Comprehensive Cancer Center	Charlottesville	Virginia	22903	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06888921, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 31, 2026 · Synced Jun 25, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06888921 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →